glp-1 cardiovascular outcomes trial results august 2025 SGLT2 Inhibitors and Receptor Agonists in Cardiovascular–Kidney–Metabolic Syndrome GLP-1 Agonists in Cardiovascular Diseases:

This is where treatments like GLP-1 medications, such as Wegovy and Mounjaro, come into play

Pharmaceutical Executive

If you have documented obesity that is a health risk, then insurers are more receptive. Levin-Scherz notes the consulting firm is seeing more drug manufacturers sell GLP-1s directly to consumers, bypassing employer and insurer decisions

[19] [20] Metformin helps improve insulin sensitivity and glycaemic control without causing hypoglycaemia

Cell Microbiol

(See Table 1 for consolidated figures.) Other companies: Sanofi (once-sharing Europe insulin production with Novo) has limited GLP-1 exposure (insulin analog and one weekly GLP-1) and has not announced major capex in this area